ライフサイエンスコーパス: DNA gyrase

1 laxing enzyme (eukaryotic topoisomerase I or DNA gyrase).

2 ovobiocin, which targets the GyrB subunit of DNA gyrase.

3 ugh validated drug targets such as bacterial DNA gyrase.

4 itors of the bacterial type II topoisomerase DNA gyrase.

5 ition of the bacterial type-II topoisomerase DNA gyrase.

6 otics and is a well-established inhibitor of DNA gyrase.

7 emic negative supercoil energy introduced by DNA gyrase.

8 is the pharmacophore for targeting bacterial DNA gyrase.

9 at minimally contained T7 RNA polymerase and DNA gyrase.

10 cent of those seen in structures of MutL and DNA gyrase.

11 h are the putative target binding motifs for DNA gyrase.

12 coumermycin A1, an antibiotic that inhibits DNA gyrase.

13 t interacts with the target bacterial enzyme DNA gyrase.

14 e; the putative target of this antibiotic is DNA gyrase.

15 for clinically useful antibiotics that block DNA gyrase.

16 a interaction with the type II topoisomerase DNA gyrase.

17 elated to the ATP-binding motif of bacterial DNA gyrase.

18 the spirochete and functions as a subunit of DNA gyrase.

19 l environment via changes in the activity of DNA gyrase.

20 CcdB is a bacterial toxin that targets DNA gyrase.

21 ed within the gene encoding the A subunit of DNA gyrase.

22 to that of an ATPase-containing fragment of DNA gyrase.

23 r protein CcdB with its intracellular target DNA gyrase.

24 ts and were found to be potent inhibitors of DNA gyrase.

25 rs, consistent with allosteric inhibition of DNA gyrase.

26 the amino acid sequence of the A subunit of DNA gyrase.

27 in mapped in gyrB, one of the genes encoding DNA gyrase.

28 e quinolone group of antibacterial agents is DNA gyrase.

29 lly modified peptide that inhibits bacterial DNA gyrase.

30 antibiotics which target the GyrA subunit of DNA gyrase.

31 ed by Streptomyces antibioticus that targets DNA gyrase.

32 Against Gram-negative microorganisms and DNA gyrase a preference for S-absolute configuration was

33 complexed with the N-terminal domain of the DNA gyrase A protein (GyrA) suggested that four SD8 mole

34 atural aminocoumarin that inhibits bacterial DNA gyrase, a member of the GHKL proteins superfamily.

35 rial agents that act by inhibiting bacterial DNA gyrase, a target of clinical significance.

36 d in terms of current mechanistic models for DNA gyrase action and the possible in vivo roles of the

37 ion, the reaction selectivity for a model of DNA gyrase action that assumes existence of a free loop

38 yrI (also called sbmC) gene product inhibits DNA gyrase activity in vitro, while the rob protein appe

39 fective for the DNA relaxation activity, and DNA gyrase activity is reduced; second, the suppressor p

40 chemical network) resulting in inhibition of DNA gyrase activity, the primary target of fluoroquinolo

41 hthyridones that kills Mtb by inhibiting the DNA gyrase activity.

42 yme-dependent homeostatic mechanisms such as DNA-gyrase activity.

43 DNA gyrases also bind to DNA at the non-homologous C-ter

44 hich we detected catenation was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV).

45 d both inhibit bacterial growth by attacking DNA gyrase and by stimulating enzyme-induced breaks in b

46 omal gyrB gene that encodes the B subunit of DNA gyrase and confers resistance to the antibiotic coum

47 cdB can stabilise a cleavage complex between DNA gyrase and DNA in a manner distinct from quinolones

48 ssaying DNA supercoiling by Escherichia coli DNA gyrase and DNA relaxation by eukaryotic topoisomeras

49 agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition tha

50 y and explains both its inhibitory effect on DNA gyrase and fluoroquinolone resistance resulting from

51 nds were tested for their ability to inhibit DNA gyrase and found to exhibit significant reduction in

52 d not show significant inhibition of E. coli DNA gyrase and hTop 1 even up to 100 muM.

53 f the bgl operon occur in the genes encoding DNA gyrase and in the gene encoding the nucleoid associa

54 the antibiotic fluoroquinolone by binding to DNA gyrase and inhibiting its activity.

55 MfpA binds to DNA gyrase and inhibits its activity.

56 This protein binds to DNA gyrase and inhibits its activity.

57 as a molecular 'clamp' mechanism, similar to DNA gyrase and MutL, whose opening and closing by transi

58 throughput microtitre plate-based assays for DNA gyrase and other DNA topoisomerases.

59 h rate but bind to different target enzymes (DNA gyrase and penicillin-binding proteins, respectively

60 How Qnr protects DNA gyrase and the prevalence of this resistance mechani

61 the toxin CcdB prevents CcdB from inhibiting DNA gyrase and thereby averts cell death.

62 Rare temperature-sensitive alleles of DNA gyrase and Topo IV (the two essential type II topois

63 acteria possess two type IIA topoisomerases, DNA gyrase and topo IV, that together help manage chromo

64 ts provide a physiologic distinction between DNA gyrase and topo IV.

65 f unlinking of various topoisomers of DNA by DNA gyrase and Topo IV.

66 Quinolone antimicrobial drugs target both DNA gyrase and topoisomerase IV (Topo IV) and convert th

67 DNA gyrase and topoisomerase IV (Topo IV) are cellular t

68 We found that both DNA gyrase and topoisomerase IV (topo IV) promote replic

69 In bacteria, DNA gyrase and topoisomerase IV act ahead of the fork to

70 s, exemplified by 34, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activ

71 YejK interacts with all the subunits of both DNA gyrase and topoisomerase IV and has measurable effec

72 /ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by mark

73 Bacterial DNA gyrase and topoisomerase IV are essential enzymes th

74 Bacterial DNA gyrase and topoisomerase IV are well-characterized c

75 DNA gyrase and topoisomerase IV control bacterial DNA to

76 Bacterial DNA gyrase and topoisomerase IV control the topological

77 improved inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria.

78 mpound 27 was the most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S.

79 Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive

80 nolone antibiotics otherwise known to target DNA gyrase and topoisomerase IV in bacterial cells.

81 rahydropyran-based molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display e

82 Research into DNA gyrase and topoisomerase IV inhibitors has become a

83 for structure-based optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibact

84 this class of compounds toward balanced dual DNA gyrase and topoisomerase IV inhibitors with antibact

85 esent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors.

86 nolones are antibacterial agents that attack DNA gyrase and topoisomerase IV on chromosomal DNA.

87 trategy for investigating the well-validated DNA gyrase and topoisomerase IV targets while preventing

88 t Staphylococcus aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified.

89 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the

90 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity

91 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibact

92 ibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to b

93 n of a new class of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in t

94 organisms, (b) inhibitory activities against DNA gyrase and topoisomerase IV, and (c) no inhibitory a

95 floxacin, inhibit the type 2 topoisomerases, DNA gyrase and topoisomerase IV, and can cleave DNA at s

96 ch as 6 and 21 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacteria

97 rong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity agai

98 al agents that specifically target bacterial DNA gyrase and topoisomerase IV.

99 ctivity through dual inhibition of bacterial DNA gyrase and topoisomerase IV.

100 unds against the ATP binding pockets of both DNA gyrase and topoisomerase IV.

101 cessivity of the DNA helicase might overcome DNA gyrase and topoisomerase IV.

102 nhibitors that bind to the catalytic site of DNA gyrase and topoisomerase IV.

103 ary phase, whereas during exponential growth DNA gyrase and/or transcription equalizes supercoiling a

104 t bacterial type II DNA topoisomerases (e.g. DNA gyrase) and are among the most important antibiotics

105 related with excess negative supercoiling by DNA gyrase, and the gyrase inhibitor, coumermycin, rever

106 to ofloxacin, a fluoroquinolone inhibitor of DNA gyrase, and to topoisomerase IV and were almost comp

107 antibiotics novobiocin and clorobiocin with DNA gyrase are illustrative of the importance of bound w

108 Fluoroquinolone antibacterials, which target DNA gyrase, are critical agents used to halt the progres

109 Members of one class of the enzymes, DNA gyrases, are configured to carry out an intramolecul

110 cterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the

111 originally annotated as potentially encoding DNA gyrase: ATGYRA, ATGYRB1, ATGYRB2, and ATGYRB3.

112 reveal unique features of the S. pneumoniae DNA gyrase ATPase and demonstrate the utility of the ass

113 rcular activity acting through inhibition of DNA Gyrase B (GyrB) ATPase.

114 ever, inhibitors of its ATP binding subunit, DNA gyrase B (GyrB), have so far not reached clinical us

115 4,5,6,7-tetrahydrobenzo[1,2-d]thiazole-based DNA gyrase B inhibitors, we replaced their central core

116 further optimization of this novel class of DNA gyrase B inhibitors.

117 ides were designed and prepared as potential DNA gyrase B inhibitors.

118 cture of the 43 kDa N-terminal domain of the DNA gyrase B protein (GyrB) shows that the majority of t

119 Glu in the highly conserved QTK-loop in the DNA gyrase B protein homologous domain of Drosophila top

120 We have examined the role of the DNA gyrase B protein in cleavage and religation of DNA u

121 ure of the 43 kDa N-terminal fragment of the DNA gyrase B protein shows a large cavity within the pro

122 -oxoacetic acid (24) in complex with E. coli DNA gyrase B revealed the binding mode of the inhibitor

123 on crystal structure in complex with E. coli DNA gyrase B was obtained, revealing details of its bind

124 Using information on a related ATPase, DNA gyrase B, we selected three conserved residues in hs

125 ow micromolar inhibitors of Escherichia coli DNA gyrase based on the 5,6,7,8-tetrahydroquinazoline an

126 se catenated molecules become supercoiled by DNA gyrase before they undergo a complete decatenation b

127 nt) sequence of the Treponema denticola (Td) DNA gyrase beta-subunit gene (gyrB) has been determined.

128 elegans homologues of pyruvate carboxylase, DNA gyrase, beta-adrenergic receptor kinase, and human h

129 impart the noviose decorations required for DNA gyrase binding and antibiotic activity.

130 A strong DNA gyrase-binding site (SGS) is located midway between

131 atalytic domain across the DNA gate, whereas DNA gyrase binds to DNA not only at the amino-terminal c

132 te sites was cleaved specifically by E. coli DNA gyrase both in vitro and in vivo.

133 dB that fail to bind to its cellular target, DNA gyrase, but retain binding to the antitoxin, CcdA.

134 660/661 have been predicted to form a second DNA gyrase, but the reconstitute holoenzyme decatenated

135 is an orally active antibiotic that inhibits DNA gyrase by binding the ATP-binding site in the ATPase

136 mutants, second, the specific inhibition of DNA gyrase by novobiocin, and third, the genetic removal

137 and coumermycin A(1) target the B subunit of DNA gyrase by presentation of the 5-methyl-pyrrolyl-2-ca

138 unctional antibiotics that inhibit bacterial DNA gyrase by preventing DNA binding to the enzyme.

139 re broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA-cleavage complexes, but th

140 ported specific labeling of Escherichia coli DNA gyrase by the ATP affinity analog pyridoxal 5'-dipho

141 MccB17 inhibits its cellular target, DNA gyrase, by trapping the enzyme in a complex that is

142 imidodiphosphate (ADPNP) to Escherichia coli DNA gyrase can lead to a limited noncatalytic supercoili

143 DNA gyrase catalyses DNA supercoiling by passing one seg

144 DNA gyrase catalyzes ATP-dependent negative supercoiling

145 action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitize

146 o locate, with single nucleotide resolution, DNA gyrase cleavage sites (GCSs) throughout the Escheric

147 s, targeted the GyrA subunit and stalled the DNA-gyrase cleavage complex.

148 Analysis of multiple DNA gyrase co-crystal structures, including asymmetric c

149 at inhibition occurs specifically at the DNA-DNA gyrase complex and is not attributable to nonspecifi

150 ic acid monohydroxamides can bind to the DNA-DNA gyrase complex in a similar fashion as that hypothes

151 E)" fusion truncate of Staphyloccocus aureus DNA gyrase complexed with DNA and diverse inhibitors hav

152 Covalent topoisomerase I and DNA gyrase complexes are converted into double-strand br

153 rentiate between the C-terminus of Hsp90 and DNA gyrase, converted a well-established gyrase inhibito

154 It is able to stabilize the transient DNA gyrase-DNA cleavage complex, a very efficient mode o

155 X-ray crystallography of DNA gyrase-DNA complexes shows the compounds binding to

156 However, E. coli DNA gyrase essentially failed to negatively supercoil 35

157 sulted in equipotent nanomolar inhibitors of DNA gyrase from Escherichia coli displaying improved inh

158 The IC50 values of compounds on DNA gyrase from Escherichia coli were in the low micromo

159 rified Qnr-His(6) protected Escherichia coli DNA gyrase from inhibition by ciprofloxacin.

160 hat both contribute to protection of E. coli DNA gyrase from quinolones.

161 compounds, the inhibitory activities against DNA gyrase from Staphylococcus aureus and topoisomerases

162 ty protein McbG, which is thought to protect DNA gyrase from the action of microcin B17.

163 ication of a 176-base pair fragment from the DNA gyrase gene of Neisseria gonorrhoeae was performed a

164 Quinolone antibacterial drugs target both DNA gyrase (Gyr) and topoisomerase IV (Topo IV) and form

165 The ability of DNA gyrase (Gyr) to wrap the DNA strand around itself al

166 east 3 mutations in the target proteins-2 in DNA gyrase (GyrA) and 1 in topoisomerase IV (ParC), whic

167 Sequencing of the gene encoding subunit A of DNA gyrase (gyrA) revealed a mutation associated with fl

168 ta subunits of the RNA polymerase (RpoB) and DNA gyrase (GyrB) and with the 16S rRNA-based phylogeny.

169 The B subunit of DNA gyrase (GyrB) consists of a 43 kDa N-terminal domain

170 Likewise, inhibition of DNA gyrase had no detectable effect on Erp expression.

171 of drug-DNA interaction in the A subunit of DNA gyrase has previously been identified from crystallo

172 Earlier results, however, indicated that DNA gyrase has the primary role in unlinking the catenat

173 ocoumarin antibiotics, compounds that target DNA gyrase in bacteria.

174 acterial drugs such as nalidixic acid target DNA gyrase in Escherichia coli.

175 The lead compound inhibited DNA gyrase in gel-based assays, with an IC(50) of 3.16 +

176 ecting the interactions of Qnr proteins with DNA gyrase in gram-negative bacteria.

177 Because the primary target of quinolones is DNA gyrase in Gram-negative strains, we tested the abili

178 are excellent targets for chemotherapy, and DNA gyrase in particular is a well-validated target for

179 ecomes more sensitive to the level of active DNA gyrase in the cell.

180 e establish by genetic means that CL targets DNA gyrase in the gram-positive bacterium Streptococcus

181 cient binding, cleavage, and supercoiling by DNA gyrase in vitro.

182 rococci clinical isolates and inhibit mutant DNA gyrase in-vitro.

183 emonstrated that novobiocin, an inhibitor of DNA gyrase, inhibited in vitro DNA replication by preven

184 In DNA gyrase-inhibited cells, the pairing prevented diffus

185 etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agen

186 The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity ac

187 agents and operate at least in part through DNA gyrase inhibition, leading to the accumulation of si

188 ine whether these moieties are important for DNA gyrase inhibition, these compounds were tested for t

189 toxin activities including RNA scission and DNA gyrase inhibition.

190 hich we have previously demonstrated to be a DNA gyrase inhibitor in vitro, suggesting that ParE1/3 i

191 Simocyclinone D8 (SD8), a potent DNA gyrase inhibitor made by Streptomyces antibioticus,

192 ntrols the export of simocyclinone, a potent DNA gyrase inhibitor made by Streptomyces antibioticus.

193 ase of the former gene, as well as using the DNA gyrase inhibitor novobiocin.

194 Simocyclinone D8 is a potent DNA gyrase inhibitor produced by Streptomyces antibiotic

195 Simocyclinone D8 (SD8) is a potent DNA gyrase inhibitor produced by Streptomyces antibiotic

196 inone C4, which is essentially inactive as a DNA gyrase inhibitor, also induces simX expression in vi

197 7-oxo-SD8 was essentially inactive as a DNA gyrase inhibitor, and the reduction of the keto grou

198 Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site

199 Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously

200 Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90

201 A DNA gyrase inhibitor, novobiocin, was previously shown t

202 The DNA gyrase inhibitor, novobiocin, was recently shown to

203 crocin B17 (MccB17) is a ribosomally encoded DNA-gyrase inhibitor.

204 f AZD0914 upon removal of magnesium from the DNA-gyrase-inhibitor complex.

205 hrombin inhibitors, HIV protease inhibitors, DNA gyrase inhibitors and many others.

206 an smc null mutant was hypersensitive to the DNA gyrase inhibitors coumermycin A1 and norfloxacin.

207 ly, (-)-1 was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminoc

208 This novel class of DNA gyrase inhibitors was extensively investigated by va

209 itial hits resulted in low nanomolar E. coli DNA gyrase inhibitors, some of which exhibited micromola

210 this basis we present a model for the AhQnr:DNA gyrase interaction where loop1 interacts with the gy

211 ce factors bind to and disrupt the quinolone-DNA-gyrase interaction is proposed.

212 DNA gyrase introduces negative supercoiling into circula

213 Bacterial DNA gyrase introduces negative supercoils into chromosom

214 DNA supercoiling by DNA gyrase involves the cleavage of a DNA helix, the pas

215 Supercoiling by DNA gyrase involves the passage of one segment of double

216 t a scheme for the DNA cleavage chemistry of DNA gyrase involving two metal ions.

217 DNA gyrase is a bacterial DNA topoisomerase that catalyz

218 DNA gyrase is a clinically validated target for developi

219 DNA gyrase is a DNA topoisomerase present in bacteria an

220 DNA gyrase is a molecular machine that uses the energy o

221 DNA gyrase is a remarkable enzyme, catalysing the seemin

222 DNA gyrase is a type II DNA topoisomerase from bacteria

223 Bacterial DNA gyrase is a well-established and validated target fo

224 Bacterial DNA gyrase is a well-known and validated target in the d

225 se ATP during their reactions; however, only DNA gyrase is able to harness the free energy of hydroly

226 DNA gyrase is an essential bacterial enzyme composed of

227 DNA gyrase is an essential bacterial enzyme required for

228 An important antibiotic target, DNA gyrase is an essential bacterial enzyme that introdu

229 al product antibiotics that target bacterial DNA gyrase is assembled from tyrosine by nonribosomal pe

230 Negative supercoiling by DNA gyrase is essential for maintaining chromosomal comp

231 the dimerization domain of the B subunit of DNA gyrase is fused to the cytoplasmic domain of VEGFRs

232 Relaxation of negatively supercoiled DNA by DNA gyrase is inhibited, whereas the extent of supercoil

233 ed circular DNA templates in the presence of DNA gyrase is known to stimulate negative DNA supercoili

234 These results suggest that DNA gyrase is the main intracellular target of MccB17.

235 Inhibition of the ATPase activity of DNA gyrase is the mechanism by which coumarin-class anti

236 DNA gyrase is the only topoisomerase able to introduce n

237 DNA gyrase is the only topoisomerase that can introduce

238 DNA gyrase is the only type II topoisomerase in Mycobact

239 When DNA gyrase is trapped on bacterial chromosomes by quinol

240 DNA gyrase is unique among enzymes for its ability to ac

241 DNA gyrase is unique among type II topoisomerases in tha

242 o biochemical methods; i.e., DNA-nicking and DNA-gyrase methods to examine whether certain sequence-s

243 In order to negatively supercoil DNA, gyrase must wrap a length of DNA around itself in a

244 t, the utilization of topoisomerase I and/or DNA gyrase mutants, second, the specific inhibition of D

245 The DNA gyrase negative supercoiling mechanism involves the

246 DNA gyrase negatively supercoils DNA in a reaction coupl

247 he synthesis and inhibitory activity against DNA gyrase of a series of diphenic acid monohydroxamides

248 t study has analysed the action of bacterial DNA gyrase on a single substrate DNA molecule, discrimin

249 strains or drugs that specifically inhibited DNA gyrase or bound to DNA directly, thereby affecting c

250 s either by interfering with the activity of DNA gyrase or by facilitating the relaxation reaction.

251 was mostly normal in cells with inactivated DNA gyrase or in mukB-null mutants lacking topA, althoug

252 somerase conflictingly categorized as either DNA gyrase or topo IV.

253 ight inhibit transcription, DNA replication, DNA gyrase or topoisomerase I; however, we found no furt

254 Using strains in which either DNA gyrase or topoisomerase IV, or both, were resistant

255 f both forks required the presence of either DNA gyrase or topoisomerase IV, suggesting that modulati

256 In silico docking of indole on DNA gyrase predicts that indole docks perfectly to the A

257 le resulting in an A271E substitution in the DNA gyrase protein generated a strain unable to grow on

258 We show here that in the absence of DNA gyrase, replication fork progression from oriC on a

259 ing catalase-peroxidase and the A subunit of DNA gyrase, respectively.

260 enzyme as relaxed circular DNA treated with DNA gyrase, resulted in the highest levels of ATPase act

261 In Escherichia coli topA strains, DNA gyrase selectively converts the positively supercoil

262 er drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cle

263 ine-naphthyridine agents, which target novel DNA gyrase sites, other novel quinolones that have high

264 otide internal fragment of the gene encoding DNA gyrase subunit B (GyrB) for VGS species-level identi

265 n reading frame with significant homology to DNA gyrase subunit B (gyrB) of Helicobacter pylori.

266 subsequent adenylylation of its target, the DNA gyrase subunit GyrB.

267 eviously reported experiments, inhibition of DNA gyrase supercoiling activity by wild-type MccB17 als

268 subset of BBZ compounds inhibited S. aureus DNA gyrase supercoiling activity with IC(50) values in t

269 example in which misfolding of one protein, DNA gyrase, suppresses a deficiency of another, topoisom

270 nt N78 are homologous to two key residues of DNA gyrase that affect quinolone sensitivity, we generat

271 l mechanism of action, inhibiting the mutant DNA gyrase that confers FQR.

272 at A. thaliana encodes an organelle-targeted DNA gyrase that is the target of the quinolone drug cipr

273 DNA gyrase, the bacterial enzyme that supercoils DNA, is

274 We identified over 40 compounds that target DNA gyrase, the cell wall, tryptophan, folate biosynthes

275 tenation activity of Topo IV but not that of DNA gyrase, the other type II topoisomerase in the cell.

276 ves quinolone inhibition of Escherichia coli DNA gyrase, thus providing an appropriate model system f

277 de a physical explanation for the ability of DNA gyrase to constrain a positive superhelical DNA wrap

278 perate through both inhibition of binding of DNA gyrase to DNA and accumulation of single-stranded DN

279 ch corresponds to the A subunit of bacterial DNA gyrase, to identify amino acid side chains that augm

280 instance, analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antiba

281 mutations in the gyrA and parC genes of the DNA gyrase/topoisomerase IV complex that occurred in the

282 ross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically.

283 eliminated the protective effect of QnrB1 on DNA gyrase toward inhibition by quinolones, whereas dele

284 DNA gyrase unlinks replicating DNA by introducing negati

285 DNA gyrase uses the energy of ATP hydrolysis to introduc

286 nalysis of high-speed structural dynamics of DNA gyrase using AuRBT revealed an unanticipated transie

287 e have analysed the DNA cleavage reaction of DNA gyrase using oligonucleotides annealed to a single-s

288 The mechanism of inhibition of DNA gyrase was distinct from the fluoroquinolones, as sh

289 rase IV were efficient at this task, whereas DNA gyrase was very inefficient at precatenane removal.

290 in sequence to the GyrA and GyrB subunits of DNA gyrase, we have used DNA sequence analysis to identi

291 ic unit (REP1) of the same RIB element binds DNA gyrase weakly.

292 homology, CT189/190 are the two subunits of DNA gyrase, whereas CT643 is a topoisomerase I.

293 n both parC (DNA topoisomerase IV) and gyrA (DNA gyrase), which were shown previously to confer fluor

294 differ from eukaryotes by having the enzyme DNA gyrase, which catalyses the ATP-dependent negative s

295 The gyrA gene encodes one subunit of DNA gyrase, which is a primary target for fluoroquinolon

296 up interacts directly with the target enzyme DNA gyrase, which is a validated drug target.

297 The C-terminal domain of the A subunit of DNA gyrase, which we term Gac, is naturally synthesized

298 in is a nanomolar inhibitor of the bacterial DNA gyrase with a strong activity against various Gram-n

299 lass of antibacterial thiophenes that target DNA gyrase with a unique mechanism of action and have ac

300 a biochemical analysis of the interaction of DNA gyrase with the Mu SGS, pSC101 and pBR322 sites.